Substances
Concerta vs. Ritalin for ADHD Treatment in Adults
Medically Reviewed By
Written By
Last medically reviewed September 1, 2025
Substances
Medically Reviewed By
Written By
Last medically reviewed September 1, 2025
ADHD is a chronic mental health condition characterized by inattention, hyperactivity, and impulsivity. This causes people to have difficulty focusing. Some describe it as having thoughts that won’t stop, making it hard to pay attention. This often leads to a decline in work performance, social isolation, and worsening mental health.
According to the American Psychiatric Association, more than 6% of U.S. adults have an ADHD diagnosis, and about half of these diagnoses are made during adulthood.
While there is no cure for ADHD, its symptoms can be effectively managed with FDA-approved medications and behavioral therapy. Ritalin and Concerta are brand names for the generic drug methylphenidate, which is commonly prescribed for attention-deficit hyperactivity disorder (ADHD).
Though both medications are effective in managing ADHD symptoms, they are not identical.
Concerta is an extended-release form of methylphenidate. It is classified as a Schedule II controlled substance because of its high potential for abuse, although it has accepted medical uses.
Treatment typically begins with a therapeutic dose of 18 to 36 mg once a day, in the morning. Doses can be increased in 18 mg increments each week, up to a maximum of 72 mg per day. As a long-acting medication, Concerta controls symptoms for up to 12 hours.
Ritalin, in contrast, is an immediate-release, short-acting version of methylphenidate. It is also a Schedule II controlled substance. Patients typically start with a therapeutic dose of 10 to 20 mg daily, divided into two doses, taken before breakfast and lunch. Doses can be increased by 5 to 10 mg per week, up to a maximum of 60 mg per day, divided into 2–3 doses. The effects of Ritalin generally last 3 to 4 hours.
Both medications are effective for managing ADHD symptoms, but they differ in duration of action, dosing schedule, and formulation. This difference can help doctors tailor treatment to individual patient needs.
According to cognitive neuroscientist Michael Frank of Brown University, Ritalin works by increasing the amount of dopamine released in a region of the brain called the striatum. This region is involved in cognition, motivation, and action. Studies have shown that the chemical messenger dopamine transfers information between neurons, influencing both thinking and behavior.
Concerta works in a very similar way, increasing the availability of brain chemicals that are important for focus and concentration, such as dopamine.
Both medications belong to a class of drugs called central nervous system stimulants. They work by preventing the brain from reabsorbing norepinephrine and dopamine, which helps improve attention and focus. Since the medications have different formulations and release mechanisms, the time it takes for a person to experience these benefits can vary.
Medications in the stimulant category often carry the risk of causing unpleasant, though generally tolerable, side effects. Since Concerta and Ritalin are both stimulants, users may experience some side effects until their bodies adjust to the medication.
The most common side effects include:
Gastrointestinal upset can sometimes lead to weight loss while taking these medications.
There are also a number of rare but serious side effects that require immediate medical attention if experienced, including:
According to the National Alliance on Mental Illness, medications like methylphenidate, including Ritalin and Concerta, should be avoided by individuals with heart disease, heart defects, uncontrolled high blood pressure, or other heart or blood vessel disorders. If you are taking other medications, Ritalin and Concerta can cause adverse drug interactions. Contact your healthcare provider for guidance on how to space them apart.
Methylphenidate, in both its generic and brand forms, is a Schedule II controlled substance. A controlled substance is any drug or chemical regulated by the government due to its potential for abuse or misuse. Drugs with abuse potential are categorized into five schedules, which classify substances based on their risk of abuse and dependence.
Schedule I drugs have the highest potential for abuse and no accepted medical use. Schedule V drugs have the lowest potential for abuse, limited physical dependence, and accepted medical use.
Both Concerta and Ritalin fall under Schedule II, meaning they have a high potential for abuse and can lead to severe psychological or physical dependence, though they have accepted medical uses. They also carry a black box warning due to their potential for abuse and dependence.
According to the National Alliance on Mental Illness, long-term use of methylphenidate can lead to physical dependence. This occurs when a person experiences withdrawal symptoms, such as changes in mood or sleep, after suddenly stopping the medication. Individuals may also experience cravings, limited control over use, or compulsive use despite the risks and adverse side effects.
People who have certain medical conditions should avoid using methylphenidate in any form. These conditions include:
Children under the age of 6 should generally avoid the medication, because studies on its safety and effectiveness in this age group are limited. Similarly, people who are noticeably tense, agitated, or anxious may require an alternative treatment.
The medication is classified as a Category C drug, meaning there is limited research on its effects during pregnancy. As a result, its use in this population should be carefully evaluated. Breastfeeding women should maintain a relative infant dose below 10% for safety.
If you’re in one of these populations and a healthcare professional has prescribed one of these medications for you, they’ve determined that the benefits outweigh the risks.
According to a study published in Frontiers in Psychiatry, methylphenidate misuse and abuse have been increasing, particularly among patients with dual diagnoses — those with co-occurring psychiatric disorders and substance use disorders. Research indicates that individuals in this population are at an elevated risk for methylphenidate misuse, especially formulations that produce a rapid high, such as Ritalin. Reasons for misuse vary, but young adults often use the drug to enhance cognition or for recreational purposes, including inducing a euphoric high.
Individuals who chronically abuse stimulants may develop a stimulant use disorder.
Symptoms of this disorder can include:
People abusing methylphenidate may also engage in behaviors such as the following:
Chronic abuse of stimulants can lead to overdose, which may produce life-threatening symptoms such as the following, or even death:
Recovering from methylphenidate addiction is a journey that can be navigated successfully with the right support.
At Southeast Addiction Center, we offer a comprehensive range of services to help you recover and maintain sobriety, including medication-assisted treatment (MAT), peer support groups, and relapse prevention programs.
These services are available at multiple levels of care, including partial hospitalization, intensive outpatient, and traditional outpatient programs, to meet your individual needs.
Contact us today to learn more about how we can support your recovery.
You don’t have to face this journey alone — we’re here to help.
Ritalin and Concerta are both forms of methylphenidate. However, they are not identical. Ritalin is a fast-acting version of the drug, while Concerta is an extended-release or long-acting version.
Yes, they are both Schedule II controlled substances, which have the potential for misuse and abuse.
Anyone with a heart condition or blood vessel condition and anyone who is pregnant or breastfeeding should use an alternative treatment for ADHD.
[1] American Psychiatric Association. (2022 Jun). What is ADHD? Retrieved from https://www.psychiatry.org/patients-families/adhd/what-is-adhd#:~:text=Attention%2Ddeficit%2Fhyperactivity%20disorder%20(ADHD)%20is%20one%20of,in%20the%20moment%20without%20thought on 2025 Sep 9.
[2] StatPearls. (2024 Oct 9). Methylphenidate. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK482451/ on 2025 Sep 9.
[3] Drugs.com. (2023 Aug 3). Concerta. Retrieved from https://www.drugs.com/concerta.html on 2025 Sep 9.
[4] Medical News Today. (2025 Aug 20). What to Know About the Concerta Crash. Retrieved from https://www.medicalnewstoday.com/articles/325673 on 2025 Sep 9.
[5] Drugs.com. (2024 Mar 22). Ritalin. Retrieved from https://www.drugs.com/ritalin.html on 2025 Sep 9.
[6] Wolraich, M. L., & Doffing, M. A. (2004). Pharmacokinetic Considerations in the Treatment of Attention-Deficit Hyperactivity Disorder with Methylphenidate. CNS Drugs, 18(4), 243–250. Retrieved from https://doi.org/10.2165/00023210-200418040-00004 on 2025 Sep 9.
[7] Brown University. (2020 Mar 19). With Ritalin And Similar Medications, The Brain Focuses On Benefits Instead Of Costs Of Work, Study Finds. Retrieved from https://www.brown.edu/news/2020-03-19/ritalin on 2025 Sep 9.
[8] Medical News Today. (2024 Apr 11). What To Know About CNS Stimulants. Retrieved from https://www.medicalnewstoday.com/articles/cns-stimulants#types-and-examples on 2025 Sep 9.
[9] Medical News Today. (2025 Mar 20). How Does Concerta Work? Retrieved from https://www.medicalnewstoday.com/articles/drugs-concerta-how-it-works#how-it-works on 2025 Sep 9.
[10] National Alliance on Mental Health (NAMI). (2024 Jan 20). Methylphenidate or Dexmethylphenidate. Retrieved from https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/methylphenidate-or-dexmethylphenidate-concerta-ritalin-and-others/ on 2025 Sep 9.
[11] StatPearls. (2023 Jul 30). Drug Enforcement Administration Drug Scheduling. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK557426/ on 2025 Sep 9.
[12] Frontiers in Psychiatry. (2024 Nov 17). Methylphenidate Abuse And Misuse In Patients Affected With A Psychiatric Disorder And A Substance Use Disorder: A Systematic Review. Retrieved from https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1508732/full on 2025 Sep 9.
[13] Treatment for Stimulant Use Disorders (SAMHSA). (n.d.). Chapter 3—Medical Aspects of Stimulant Use Disorders. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK576550/ on 2025 Sep 9.






